Chapter 3. Bacillus Calmette–Guérin Immunotherapy of Genitourinary Cancer

  1. Rimas Orentas PhD2,
  2. James W. Hodge PhD3 and
  3. Bryon D. Johnson PhD4
  1. Donald L. Lamm MD Clincial Professor

Published Online: 1 MAR 2007

DOI: 10.1002/9780470170113.ch3

Cancer Vaccines and Tumor Immunity

Cancer Vaccines and Tumor Immunity

How to Cite

Lamm, D. L. (2008) Bacillus Calmette–Guérin Immunotherapy of Genitourinary Cancer, in Cancer Vaccines and Tumor Immunity (eds R. Orentas, J. W. Hodge and B. D. Johnson), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470170113.ch3

Editor Information

  1. 2

    Departments of Pediatrics, Medicine, Microbiology and Molecular Genetics, Medical College of Wisconsin and the Children's Research Institute, Children's Hospital of Wisconsin, Milwaukee, WI, USA

  2. 3

    Department of Medical Biology, University of Tennessee Medical Center and Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

  3. 4

    Department of Pediatrics, Medical College of Wisconsin and the Children's Research Institute, Children's Hospital of Wisconsin., Milwaukee, WI, USA

Author Information

  1. University of Arizona and President, BCG Oncology, Phoenix, AZ, USA

Publication History

  1. Published Online: 1 MAR 2007
  2. Published Print: 22 JAN 2008

ISBN Information

Print ISBN: 9780470074749

Online ISBN: 9780470170113

SEARCH

Keywords:

  • genitourinary cancer and Bacillus Calmette–Guérin (BCG) immunotherapy;
  • bladder cancer BCG immunotherapy;
  • combination immunotherapy

Summary

This chapter contains sections titled:

  • Introduction

  • Tuberculosis

  • BCG and Cancer: General Aspects

  • BCG in Bladder Cancer

  • BCG in other GU Malignancies

  • Immune Response to BCG

  • Toxicity

  • Conclusions

  • Acknowledgment

  • References